By Karim Khaledi
Histogenics Corp (NASDAQ:HSGX) was downgraded by Zacks from a “hold” rating to a “sell” rating in a report released on Thursday.
Zacks’ analyst
wrote, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “
Several other analysts have also recently commented on the stock. Analysts at Canaccord Genuity reiterated a “buy” rating and set a $16.50 price target on shares of Histogenics Corp in a research note on Tuesday, March 10th. Separately, analysts at BTIG Research set a $13.00 price target on shares of Histogenics Corp and gave the company a “buy” rating in a research note on Friday, February 27th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Histogenics Corp currently has an average rating of “Buy” and an average price target of $15.88.
Shares of Histogenics Corp (NASDAQ:HSGX) traded down 4.56% during mid-day trading on Thursday, hitting $8.16. 4,570 shares of the company’s stock traded hands. Histogenics Corp has a 52 week low of $7.04 and a 52 week high of $12.47. The stock’s 50-day moving average is $9. and its 200-day moving average is $9.. The company’s market cap is $104.01 million.
